Tildipirosin:A relatively new macrolide antibiotic for animals

Tildipirosin is a relatively new macrolide antibiotic with broad-spectrum antibacterial activity, effectively inhibiting Gram-positive bacteria (such as staphylococci and streptococci) and certain Gram-negative bacteria (such as Pasteurella multocida, Actinobacillus pleuropneumoniae, Glaesserella parasuis, etc). Based on its unique antibacterial activity and excellent pharmacokinetic properties-including a long half-life, high bioavailability, and exceptional intracellular permeability-it has demonstrated good efficacy in the prevention and treatment of respiratory diseases in large animals. In recent years, research on the pharmacokinetics, pharmacodynamics, and clinical applications of tildipirosin has increased, providing data support for dose optimization, efficacy evaluation, and safe use in animals. However, systematic summaries regarding its tissue distribution across different animal species, pulmonary concentration characteristics, antimicrobial spectrum, Pharmacokinetic/Pharmacodynamic (PK/PD) model establishment, and drug residues and withdrawal periods remain insufficient. This paper systematically reviews existing literature on tildipirosin's antibacterial activity, pharmacokinetic/pharmacodynamic characteristics, clinical efficacy, and residue safety. It aims to provide scientific evidence and practical guidance for establishing optimal dosing regimens, preventing and treating respiratory diseases, and ensuring food safety in animal-derived products.